T and B Cell-based In Vivo Assay
Creative Biolabs offers in vivo assay service with premium quality to identify immunogenic epitopes using various animal models and cutting-edge analytical techniques.
Discover the Tumor-associated Peptides Presented in Vivo
As we all know, tumor antigens are processed by antigen presentation cells and then presented on major-histocompatibility-complex class I (MHC-I) molecules, also called the human leukocyte antigen (HLA) in humans. In cancer epitope studies, most methods used for peptide-MHC studies are limited to in vitro assays to analyze the proteome-level peptide library. However, the cancer epitopes have much association with the post-translation process and could not be predicted by the genome-scale analysis of mRNA. The crucial step of antigen presentation in vivo should not be neglected if you want to identify the cancer peptides.
Fig.1 Identification of cancer antigens in vivo using the PDX mouse models.1
In Vivo Assay Services at Creative Biolabs
Our in vivo assay is dedicated to directly identifying T and B cell epitope peptides processed and presented by in vivo immune system. The advanced techniques for peptide purification and identification have provided us insight into the complex cancer epitopes.
Workflow
In Vivo Models Available
-
Multiple species of animal models are available for in vivo studies.
-
Various types of mouse models are used with high frequency, including transgenic mice and xenograft mouse models.
|
Types
|
Features
|
Functions
|
|
MHC-I Transgenic Mouse Model
|
Expressing the human HLA-A2 molecular
|
Investigating CD8+ T cell responsive antigenic epitope.
|
|
MHC-II Transgenic Mouse Model
|
Harboring the human HLA-DR molecular
|
Investigating CD4+ T cell responsive antigenic epitope.
|
|
Double Transgenic Mouse Model
|
Expressing MHC-I and MHC-II molecule
|
Monitoring the synergy function of CD8+ and CD4+ T cell responses.
|
|
Xenograft Model
|
Patient-derived tumor model
|
Providing a larger cancer antigen peptidome for screening.
|
Immunodominant Epitope Evaluation Services
Highlights of Our Services
-
Improved efficiency
-
Identify physiologically relevant cancer peptides
-
Animal models with more HLA types
-
Provide fewer but high-quality and reliable immunodominant epitope candidates
-
Comprehensively characterization of the tumor epitopes using multiple actions mechanism-related assays
Creative Biolabs has established advanced platforms to provide multiple approaches to provide an enlarged peptidome analysis of tumors and provide authentic tumor peptides for your targeted immunotherapy. For more information on the solutions of cancer antigen-related services, please contact us by e-mail.
Reference
-
Rijensky, N. M.; et al. Identification of Tumor Antigens in the HLA Peptidome of Patient-derived Xenograft Tumors in Mouse. Molecular & cellular proteomics: MCP. 2020, 19(8): 1360–1374.
For Research Use Only | Not For Clinical Use
Download our brochure